or Try an Advanced Search...

    Technical Analysis for THAR - Tharimmune, Inc.

    Grade Last Price % Change Price Change
    F 0.37 2.22% 0.01
    THAR closed up 2.22 percent on Friday, April 26, 2024, on 15 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Flat
    Historical THAR trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Wide Bands Range Expansion 2.22%
    Oversold Stochastic Weakness 2.22%
    Wide Bands Range Expansion -0.78%
    Oversold Stochastic Weakness -0.78%
    Doji - Bearish? Reversal -2.61%
    Wide Bands Range Expansion -2.61%
    Older End-of-Day Signals for THAR ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 1 day ago
    10 DMA Resistance 1 day ago
    60 Minute Opening Range Breakout 1 day ago
    Up 2% 1 day ago
    Up 1% 1 day ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    THAR Chart by TradingView
    Basic chart:

    Profile

    Tharimmune, Inc. is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors. Tharimmune has a license agreement with OmniAb, Inc. to access the company's antibody discovery technology platform against specified targets.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Immunology Solid Tumors Antibodies Autoimmune Disease Oncology Cancer Immunotherapy Antibody Hepatology Inflammatory Primary Biliary Cholangitis

    Is THAR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 15 Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
    Mar 6 Presenting on the Emerging Growth Conference 68 Day 2 on March 7 Register Now
    Mar 5 Tharimmune to Present at the Emerging Growth Conference on March 7, 2024
    Feb 20 Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate
    Feb 5 Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis
    Jan 29 Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update
    Dec 19 Perspective Therapeutics And 3 Other Stocks Under $1 Insiders Are Buying
    Dec 11 Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients
    Dec 8 Why Hello Group Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
    Nov 30 Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
    See more THAR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 12.4725
    52 Week Low 0.3439
    Average Volume 415,674
    200-Day Moving Average 3.13
    50-Day Moving Average 0.40
    20-Day Moving Average 0.40
    10-Day Moving Average 0.37
    Average True Range 0.03
    RSI (14) 41.18
    ADX 10.94
    +DI 15.54
    -DI 17.26
    Chandelier Exit (Long, 3 ATRs) 0.42
    Chandelier Exit (Short, 3 ATRs) 0.44
    Upper Bollinger Bands 0.48
    Lower Bollinger Band 0.33
    Percent B (%b) 0.27
    BandWidth 36.92
    MACD Line -0.01
    MACD Signal Line -0.01
    MACD Histogram -0.0033
    Fundamentals Value
    Market Cap 932.15 Thousand
    Num Shares 2.53 Million
    EPS -15.50
    Price-to-Earnings (P/E) Ratio -0.02
    Price-to-Sales 0.00
    Price-to-Book 0.67
    Dividend 0.00
    Dividend Yield 0.00%
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.39
    Resistance 3 (R3) 0.38 0.38 0.38
    Resistance 2 (R2) 0.38 0.37 0.38 0.38
    Resistance 1 (R1) 0.37 0.37 0.38 0.37 0.38
    Pivot Point 0.37 0.37 0.37 0.37 0.37
    Support 1 (S1) 0.36 0.36 0.36 0.36 0.36
    Support 2 (S2) 0.35 0.36 0.36 0.36
    Support 3 (S3) 0.35 0.35 0.35
    Support 4 (S4) 0.35